MarketPulse
K

$KRYS

6 articles found
1 positive
0 negative
5 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Krystal Biotech to Showcase Gene Therapy Pipeline at Major 2026 Scientific Conferences

Krystal Biotech will present gene therapy data across three major conferences in May-June 2026, highlighting programs targeting ciliary dyskinesia, cystic fibrosis, and immunotherapy.
KRYSclinical trialsgene therapy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharma's CF Dominance Faces Long-Term Threat From Gene Therapy Rivals

Vertex's cystic fibrosis market dominance faces gene therapy competition post-patent expiration, but patent protection extends through late 2030s while diversification efforts hedge risk.
VRTXKRYSkidney diseasegene therapy
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Redmile Group Doubles Down on Nurix With $63M Investment Despite Underperformance

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.
NRIXKRYSstock underperformanceclinical trial
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying